Credit Suisse Downgrades Galapagos NV (GLPG) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq drags on Wall St as AI slowdown fears hammer Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Trump slams Anthropic CEO over AI slowdown call
- Oil prices soar over 4% to 16-week high after Saudi strikes
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
September 25, 2015 10:49 AM EDTGalapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibitor Best-in-class efficacy and safety in RA in 24-week Phase 2B studies in 877 patients Phase 3 start in RA expected in early 2016
MECHELEN, Belgium, Sept. 25, 2015 (GLOBE NEWSWIRE) -- Galapagos to hold a conference call open to the public  today at 17.15 CET/11:15 AM EDT CODE: 830162
UK: +44 330 336 6025 USA: +1 719 325 2556 Belgium:... More